跳至主要内容
临床试验/NCT03520127
NCT03520127终止不适用

A Multi-center Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)

Medtronic Surgical Technologies7 个研究点 分布在 1 个国家目标入组 176 人开始时间: 2017年9月27日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
176
试验地点
7
主要终点
Lesion BIRADS score

研究概览

简要总结

The purpose of this registry study is to collect use and clinical outcomes data following breast lesion excision or sampling with the Intact BLES.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • BIRADS ≤ 5, as initially imaged
  • Subject is willing and capable of providing informed consent and has a scheduled or planned breast lesion excision or sampling where the Intact BLES is expected to be used

排除标准

  • Subjects with subglandular (pre-pectoral, or "single plane") breast implants
  • Subjects with electronic implantable devices (such as pacemakers and defibrillators)
  • Subjects who are contraindicated for surgery due to factors such as anti-coagulant use which cannot be safely reversed

结局指标

主要结局

Lesion BIRADS score

时间窗: Weeks prior to the Intact procedure

Diagnostic imaging result

Imaging lesion size

时间窗: Weeks prior to the Intact procedure

Measured in mm

Lesion histology

时间窗: Weeks prior to the Intact procedure

Lesion biopsy results

Tissue margin (as reported from histology) rate

时间窗: Weeks after the Intact procedure, up to approximately 12 weeks

Procedure margin vs. margin size, measured in mm

Underestimation rate

时间窗: Weeks after the Intact procedure, up to approximately 12 weeks

Compared to maximum lesion size, measured in mm

次要结局

未报告次要终点

研究者

发起方
Medtronic Surgical Technologies
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验